Stable tumoural response to stereotactic body radiotherapy in well-differentiated metastatic small intestine neuroendocrine tumour

#4477

Introduction: Over half of patients with Neuroendocrine tumours (NET) have unresectable or metastatic disease. SSA y PRRT are successful targeted therapy to symptoms relief and stabilise disease. Otherwise, there are emerging options of radiotherapy including hypofractionation or stereotactic body radiotherapy. The clinical evidence of radiotherapy in NEN is scarce, and there is limited published data.

Aim(s): Give evidence of oncologic outcomes after stereotactic body radiotherapy in a patient with an unresectable metastatic and functionally intestinal NET.

Materials and methods: case Report

Conference:

Presenting Author: Florez A

Authors: Sanabria D, Florez A,

Keywords: Neuroendocrine, Tumour, metastatic,